Relevant bibliographies by topics / Myeloma patients

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Myeloma patients'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Myeloma patients.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Myeloma patients"

1

Do, T. H., H. E. Johnsen, E. Kjærsgaard, E. Taaning, and I. M. Svane. "Impaired circulating myeloid DCs from myeloma patients." Cytotherapy 6, no. 3 (June 2004): 196–203. http://dx.doi.org/10.1080/14653240410006004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vlossak, Donnaleen, and Margaret I. Fitch. "Le myélome multiple : la perspective des patients." Canadian Oncology Nursing Journal 18, no. 3 (2008): 146–51. http://dx.doi.org/10.5737/1181912x183146151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Demircioğlu, Sinan, Gülçin Miyase Sönmez, Ali Doğan, Ömer Ekinci, and Cengiz Demir. "Incidence of Extramedullary Myeloma in Multiple Myeloma Patients." Van Medical Journal 26, no. 3 (2019): 337–41. http://dx.doi.org/10.5505/vtd.2019.98470.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Khoo, Weng Hua, Guy Ledergor, Assaf Weiner, Daniel L. Roden, Rachael L. Terry, Michelle M. McDonald, Ryan C. Chai, et al. "A niche-dependent myeloid transcriptome signature defines dormant myeloma cells." Blood 134, no. 1 (July 4, 2019): 30–43. http://dx.doi.org/10.1182/blood.2018880930.

Full text
Abstract:
Abstract The era of targeted therapies has seen significant improvements in depth of response, progression-free survival, and overall survival for patients with multiple myeloma. Despite these improvements in clinical outcome, patients inevitably relapse and require further treatment. Drug-resistant dormant myeloma cells that reside in specific niches within the skeleton are considered a basis of disease relapse but remain elusive and difficult to study. Here, we developed a method to sequence the transcriptome of individual dormant myeloma cells from the bones of tumor-bearing mice. Our analyses show that dormant myeloma cells express a distinct transcriptome signature enriched for immune genes and, unexpectedly, genes associated with myeloid cell differentiation. These genes were switched on by coculture with osteoblastic cells. Targeting AXL, a gene highly expressed by dormant cells, using small-molecule inhibitors released cells from dormancy and promoted their proliferation. Analysis of the expression of AXL and coregulated genes in human cohorts showed that healthy human controls and patients with monoclonal gammopathy of uncertain significance expressed higher levels of the dormancy signature genes than patients with multiple myeloma. Furthermore, in patients with multiple myeloma, the expression of this myeloid transcriptome signature translated into a twofold increase in overall survival, indicating that this dormancy signature may be a marker of disease progression. Thus, engagement of myeloma cells with the osteoblastic niche induces expression of a suite of myeloid genes that predicts disease progression and that comprises potential drug targets to eradicate dormant myeloma cells.
APA, Harvard, Vancouver, ISO, and other styles
5

Winterbottom, A. P., and A. S. Shaw. "Imaging patients with myeloma." Clinical Radiology 64, no. 1 (January 2009): 1–11. http://dx.doi.org/10.1016/j.crad.2008.07.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bayer-Garner, Ilene B., Mary R. Schwartz, Pei Lin, and Bruce R. Smoller. "CD117, but Not Lysozyme, Is Positive in Cutaneous Plasmacytoma." Archives of Pathology & Laboratory Medicine 127, no. 12 (December 1, 2003): 1596–98. http://dx.doi.org/10.5858/2003-127-1596-cbnlip.

Full text
Abstract:
Abstract Context.—CD117 (c-Kit) and lysozyme are frequently expressed by myeloblasts and are sensitive markers for the diagnosis of extramedullary myeloid tumor. The diagnosis of cutaneous plasmacytoma presents a degree of difficulty, particularly with the plasmablastic variant, which can mimic hematologic as well as epithelioid malignancies. Approximately 25% of multiple myelomas express CD117 in the bone marrow by flow cytometry. Lysozyme immunoreactivity has been previously shown in 30% of poorly differentiated myelomas, while it is nonreactive in nonmalignant plasma cells. Objective.—To ascertain whether CD117 and lysozyme can aid in the diagnosis of cutaneous plasmacytomas, particularly the plasmablastic type. Design.—Pathology reports of 2357 patients with a diagnosis of multiple myeloma were reviewed to find 13 cutaneous plasmacytomas (8 Bartl grade II, 5 Bartl grade III). Formalin-fixed, paraffin-embedded tissue sections were stained with CD117 and lysozyme on the Dako Autostainer system. Setting.—Patients with the diagnosis of multiple myeloma who developed cutaneous plasmacytoma(s). Results.—The cutaneous plasmacytomas uniformly expressed CD117 in a cytoplasmic or membranous and cytoplasmic distribution with varying degrees of staining intensity unrelated to the Bartl grade of the lesion, while they were uniformly negative for lysozyme. Conclusions.—CD117 is a sensitive marker for malignant plasma cells in paraffin-embedded tissue, while lysozyme does not help identify poorly differentiated malignant plasma cells. While CD117 alone does not distinguish extramedullary myeloid tumor from poorly differentiated myeloma, the combination of CD117 and lysozyme may allow their differentiation. The possibility of c-kit inhibitors being used in the treatment of other hematopoietic malignancies allows speculation regarding implications for the treatment of multiple myeloma.
APA, Harvard, Vancouver, ISO, and other styles
7

Войцеховский, Валерий, Valeriy Voytsekhovskiy, Татьяна Заболотских, Tat'yana Zabolotskikh, Алексей Григоренко, Aleksey Grigorenko, Екатерина Филатова, and Ekaterina Filatova. "DAMAGE OF THE BRONCHOPULMONARY SYSTEM IN PATIENTS WITH CHRONIC HEMOBLASTOSIS." Bulletin physiology and pathology of respiration 1, no. 69 (October 5, 2018): 25–35. http://dx.doi.org/10.12737/article_5b975083a62278.59044240.

Full text
Abstract:
In 185 patients with chronic hemoblastosis (chronic lymphocytic leukemia, chronic myeloid leukemia, idiopathic myelofibrosis, multiple myeloma) after autopsy, the pathology of the bronchopulmonary system was studied. It was found out that in addition to immunodeficiency, an important role in the occurrence of respiratory diseases in chronic lymphocytic leukemia, as well as in chronic myeloid leukemia and idiopathic myelofibrosis in the stage of blast crisis is played by specific leukemic infiltration of the lungs, bronchi, pleura and diaphragm; the presence of leukostasis in the vessels of medium and small caliber with violation of microcirculation; compression of the diaphragm by significantly increased spleen and liver; in some cases (especially in chronic lymphocytic leukemia) hyperplasia of the lymphoid follicles of the bronchial tree. In chronic myeloid leukemia and idiopathic myelofibrosis, hyperthrombocytosis with the development of the sludge syndrome in small vessels of the lungs is essential. Pulmonary localization of inflammatory processes in patients with multiple myeloma is facilitated by lymphoid and plasma cell infiltration of the lungs, paraproteinosis of the lungs, localization of myeloma nodes in the ribs, lung tissue and bronchi.
APA, Harvard, Vancouver, ISO, and other styles
8

Kubiczkova-Besse, Lenka, Lenka Sedlarikova, Fedor Kryukov, Lenka Radova, Jana Nekvindova, Pavel Nemec, Daniela Drandi, et al. "Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients." Blood 124, no. 21 (December 6, 2014): 2043. http://dx.doi.org/10.1182/blood.v124.21.2043.2043.

Full text
Abstract:
Abstract Background MicroRNAs (miRNAs) are a class of short, non-coding, single stranded RNAs regulating a broad spectrum of processes. Circulating miRNAs are an important emerging biomarker in cancer as well as a possible non-invasive diagnostic solution for a wide range of clinical disorders due to their high stability and association with disease state, although their source still remains uncertain. In multiple myeloma (MM), a plasma cell malignancy, circulating miRNAs have been reported to have a diagnostic and prognostic potential. It is therefore plausible to assume that they are involved in pathogenesis of this disease and thus could be used as diagnostic tool not only for MM, its extramedullary (EM) form but also for monitoring the clinical course of the disease. Therefore, in this study, we aimed to identify such miRNAs. Methods Screening analysis of 667 miRNAs was performed on 5 EM serum samples, 5 newly diagnosed MM samples and 6 healthy donors (HD) serum samples using TaqMan Low Density Arrays (TLDA) from Life Technologies. QPCR was performed for miR-130a on 118 serum samples obtained in Brno from newly diagnosed MM patients (pts) (35 pts), primary and secondary EM (35 pts), relapsed MM (18 pts) and HD (30). Further, 45 serum samples (12 diagnostic and 33 follow-up) of pts reaching VGPR/better response, enrolled in Italian CRD/MEL-200 and EMN-02 studies were used for circulating miRNA estimation. Receiver Operating Characteristic (ROC) analysis was used to calculate specificity and sensitivity of the miRNA as a biomarker. Biochemical characteristics were also available for EM and MM pts from Brno. P values <0.05 were considered as significant. Results TLDA profiling revealed 14 deregulated miRNAs (all p<0.05, adjusted p<0.41) between MM pts and EM pts, and 20 miRNAs were on the top of the list of deregulated miRNAs between EM and HD serum samples (all p<0.05, adjusted p<0.40). MiR-130a was chosen for further verification by qPCR as it was on the top of the list of deregulated miRNAs between the groups. qPCR revealed that level of miR-130a was significantly decreased in MM and EM samples when compared with HD (all p<0.005); moreover, level of miR-130a was decreased also in EM when compared with MM sera (p<0.06). To discriminate EM pts from other groups, ROC curve was calculated. It revealed that miR-130a is potent to distinguish EM pts from HD with area under the curve (AUC) = 0.805, specificity of 86.7% and sensitivity of 65.7% using cut-off value = 3377 copies/1ng of miRNA/RNA. Most importantly, miR-130a was able to distinguish EM pts from newly diagnosed MM pts with AUC = 0.628, specificity of 94.3% and sensitivity of 28.6% using cut-off value = 1438 copies/1ng of miRNA/RNA, and EM pts from MM pts in relapse with AUC = 0.702, specificity of 94.4% and sensitivity of 28.6% using cut-off value = 1438 copies/1ng of miRNA/RNA. In the cohort of EM pts, miR-130a significantly correlated with most of clinically relevant parameters; there was a positive correlation with level of hemoglobin and thrombocytes count (rs=0.397 and 0.439, all p<0.05) and a negative correlation with levels of monoclonal immunoglobulin, β2-microglobulin and C-reactive protein (rs=-0.398, -0.427 and -0.488, all p<0.05) and it was also associated with higher ISS stage (p=0.017). Further, in the analysis of miR-130a dynamics in follow-up samples from Italy, we observed increase of miR-130a levels in 8/12 MM pts during the follow-up sampling (p<0.06) in comparison with diagnostic samples, whereas in remaining 4 MM pts it remained stable or decreased. Conclusions In this study, miR-130a was decreased in serum samples of pts developing EM disease and distinguished EM pts from newly diagnosed MM pts and relapsed/progressed MM pts with specificity over 90%. Further, we observed increased level of miR-130a in the follow-up samples of MM pts. It suggests that miR-130a could be associated with EM disease; however, underlying biology and origin of miR-130a still remains to be explored. Work was supported by grants IGA NT 12130, NT 14575 and NT 13190. Disclosures Palumbo: Amgen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Array BioPharma: Honoraria; Genmab A/S: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Janssen-Cilag: Consultancy, Honoraria; Millennium Pharmaceuticals, Inc.: Consultancy, Honoraria; Onyx Pharmaceuticals: Consultancy, Honoraria; Sanofi Aventis: Honoraria.
APA, Harvard, Vancouver, ISO, and other styles
9

Kelly, Mary, and Maura Dowling. "Patients’ lived experience of myeloma." Nursing Standard 25, no. 28 (March 16, 2011): 38–44. http://dx.doi.org/10.7748/ns.25.28.38.s53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mateos, María-Victoria. "Management of asymptomatic myeloma patients." Expert Review of Hematology 8, no. 1 (November 3, 2014): 19–27. http://dx.doi.org/10.1586/17474086.2015.978852.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Myeloma patients"

1

Ågren, Brita. "Radiological evaluation of bone marrow transplanted multipel myeloma patients /." Stockholm, 1997. http://diss.kib.ki.se/1997/91-628-2609-3/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hansson, Lotta. "Natural and induced idiotype immunity in patients with multiple myeloma /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-820-3/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Abdalla, Amir Osman. "Immunological and clinical long-term effects of idiotype vaccination in multiple myeloma patients /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-114-2/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jacobson, Timothy. "A Trans-Dimensional View of Drug Resistance Evolution in Multiple Myeloma Patients." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6099.

Full text
Abstract:
Multiple Myeloma (MM) is a treatable, yet incurable, malignancy of bone marrowplasma cells. This cancer affects many patients and many succumb to relapse of tumor burden despite a large number of available chemotherapeutic agents developed for therapy. This is because MM tumors are heterogeneous and receive protection from therapeutic agents by the microenvironment and other mechanisms including homologous MM-MM aggregation. Therefore, therapy failure and frequent patient relapse is due to the evolution of drug resistance, not a lack of available drugs. To analyze and understand this problem, the evolution of drug resistance has been explored and presented herein. We seek to describe the methods through which MM cells become resistant to therapy, and how this resistance evolves throughout a patient’s treatment history. We achieve this in five steps. First we review the patient’s clinical history, including treatments and changes in tumor burden. Second, we trace the evolutionary tree of sub-clones within the tumor burden using standard of care fluorescence in situ hybridization (FISH). Thirdly, immunohistochemistry slides are stained and aligned to quantify the level of environmental protection received by surrounding cells and plasma in the bone marrow microenvironment (coined environment mediated drug resistance score [EMDR]). The fourth analysis type is produced through a novel 384-well plate ex vivo chemosensitivity assay to quantify sensitivity of primary MM cells to chemotherapeutic agents and extrapolate these findings to 90-day clinical response predictions. In addition to direct clinical application in the choice of best treatment, this tool was also used to study changes in sensitivity of patient tumors to other drugs, and it was observed that, upon relapse, in addition to developing resistance to the current line of therapy, tumors become cross-resistant to agents that they were never exposed to. Finally, MM-MM homologous aggregation is quantified to assess the level of drug resistance contributed by clustering of patient tumor cells, which causes upregulation of Bcl-2 expression and other resistance mechanisms1. The findings of such experimentation improve comprehension of the driving factors that contribute to drug resistance evolution on a personalized treatment basis. The aforementioned factors all contribute in varying degrees for unique patient cases, seven of which are presented in depth for this project. In summary: Environmental protection plays a critical initial role in drug resistance, which is followed by increase in tumor genetic heterogeneity as a result of mutations and drug-induced Darwinian selection. Eventually, environment-independent drug resistant subpopulations emerge, allowing the tumor to spread to unexplored areas of the bone marrow while maintaining inherited drug resistant phenotype2. It is our hope that these findings will help in shifting perspective regarding optimal management of MM by finding new therapeutic procedures that address all aspects of drug resistance to minimize chance of relapse and improve quality of life for patients.
APA, Harvard, Vancouver, ISO, and other styles
5

Esmaeili, Abbas. "Identifying responders to melphalan and dexamethasone for newly diagnosed multiple myeloma patients." Thesis, Kingston, Ont. : [s.n.], 2008. http://hdl.handle.net/1974/1330.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gerfen, Ashlee. "Chemomobilization with cyclophosphamide and filgrastim in multiple myeloma patients following lenalidomide treatment." The University of Arizona, 2012. http://hdl.handle.net/10150/623611.

Full text
Abstract:
Class of 2012 Abstract
Specific Aims: Autologous stem cell transplant (ASCT) is the current gold standard following induction therapy to improve survival of multiple myeloma (MM). Lenalidomide (LEN) is used for treatment of MM before ASCT, but exposure may impair autologous peripheral blood stem cell (PBSC) mobilization. Chemomobilization with cyclophosphamide (CTX) has not been evaluated in this setting. CTX + filgrastim was investigated to determine if LEN-associated mobilization impairment can be abrogated. Methods: 36 pts (group A=12 pts who received ≥2 cycles of LEN and group B=24 pts without LEN) were analyzed retrospectively. Baseline characteristics were matched (p>0.05 for all variables). All pts received CTX (median group B, 1.5g/m2; median group A, 3gm/m2(p=0.18)) and filgrastim 10μg/kg/day. Primary outcomes include number of CD34+ cells collected and number of leukapheresis sessions. Secondary outcomes include failure to collect CD34+ cells and total CD34+ cells collected after second leukapheresis. Main Results: Total median number of CD34+ cells collected in group B=9.15x106/kg CD34+ cells and group A=7.43x106/kg CD34+ cells (p=0.159). Median number of apheresis sessions in group B=2 and group A=3 (p=0.42). Two of 12 pts with antecedent LEN usage failed to collect while no patient without previous LEN exposure failed to collect (p=0.105). Total number of CD34+ cells collected after 2 apheresis sessions for group B=8.13x106/kg CD34+ cells and group A=3.34x106/kg CD34+ cells (p=0.06). Conclusions: Chemomobilization with CTX + filgrastim yields robust PBSC collections irrespective of antecedent lenalidomide. There was a trend towards lesser PBSC collection in LEN-treated pts.
APA, Harvard, Vancouver, ISO, and other styles
7

Gerfen, Ashlee, and Myke Green. "Chemomobilization with Cyclophosphamide and Filgrastim in Multiple Myeloma Patients Following Lenalidomide Treatment." The University of Arizona, 2012. http://hdl.handle.net/10150/614472.

Full text
Abstract:
Class of 2012 Abstract
Specific Aims: Autologous stem cell transplant (ASCT) is the current gold standard following induction therapy to improve survival of multiple myeloma (MM). Lenalidomide (LEN) is used for treatment of MM before ASCT, but exposure may impair autologous peripheral blood stem cell (PBSC) mobilization. Chemomobilization with cyclophosphamide (CTX) has not been evaluated in this setting. CTX + filgrastim was investigated to determine if LEN-associated mobilization impairment can be abrogated. Methods: 36 pts (group A=12 pts who received ≥2 cycles of LEN and group B=24 pts without LEN) were analyzed retrospectively. Baseline characteristics were matched (p>0.05 for all variables). All pts received CTX (median group B, 1.5g/m2; median group A, 3gm/m2(p=0.18)) and filgrastim 10µg/kg/day. Primary outcomes include number of CD34+ cells collected and number of leukapheresis sessions. Secondary outcomes include failure to collect CD34+ cells and total CD34+ cells collected after second leukapheresis. Main Results: Total median number of CD34+ cells collected in group B=9.15x106/kg CD34+ cells and group A=7.43x106/kg CD34+ cells (p=0.159). Median number of apheresis sessions in group B=2 and group A=3 (p=0.42). Two of 12 pts with antecedent LEN usage failed to collect while no patient without previous LEN exposure failed to collect (p=0.105). Total number of CD34+ cells collected after 2 apheresis sessions for group B=8.13x106/kg CD34+ cells and group A=3.34x106/kg CD34+ cells (p=0.06). Conclusions: Chemomobilization with CTX + filgrastim yields robust PBSC collections irrespective of antecedent lenalidomide. There was a trend towards lesser PBSC collection in LEN-treated pts.
APA, Harvard, Vancouver, ISO, and other styles
8

Raninga, Prahlad Vinodbhai. "Antioxidant Systems, Thioredoxin and DJ-1: Novel Therapeutic Targets in Multiple Myeloma." Thesis, Griffith University, 2017. http://hdl.handle.net/10072/366858.

Full text
Abstract:
Multiple myeloma (MM) is a plasma cell malignancy characterized by an accumulation of malignant clonal plasma cells in the bone marrow (BM). In recent years, many effective anti-MM drugs have been developed including proteasome inhibitors and immunomodulators. Introduction of the proteasome inhibitor bortezomib has improved prognosis and survival in MM patients. However, upon prolonged drug treatment, myeloma cells acquire resistance to the given treatment including bortezomib, resulting in disease relapse. Studies have shown that the BM in myeloma patients is extensively hypoxic (1% O2) compared to the BM in healthy individuals. Hypoxia is a crucial microenvironmental factor that plays an important role in MM disease progression and drug resistance. Due to the development of drug resistance, MM remains an incurable disease with the median survival of only 3 to 5 years. Thus, novel therapeutic strategies are required to kill myeloma cells growing under physiological O2 conditions, including hypoxic microenvironments, and to overcome both acquired and hypoxia-induced drug resistance to improve MM patient survival and prognosis.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Natural Sciences
Science, Environment, Engineering and Technology
Full Text
APA, Harvard, Vancouver, ISO, and other styles
9

Cho, Yu Kyoung. "Pharmacokinetics and pharmacodynamics of melphalan in multiple myeloma patients to predict clinical adverse outcomes." The Ohio State University, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=osu1468419921.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jackson, G. H. "Long term bone marrow culture studies of patients with lymphoid malignancies undergoing autologous bone marrow transplantation." Thesis, University of Newcastle Upon Tyne, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.309068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Myeloma patients"

1

McIvor, Caroleanne. Study of peripheral blood lyumphocytes in myeloma patients. [s.l: The Author], 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Going for the cure. New York: St. Martin's Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Madden, Ed. Carpe Diem: Enjoying every day with a terminalillness. Boston: Jones & Bartlett, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dancing with cancer: A healing through visualization. Dallas, Tex: Noteman Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Our interrupted fairy tale: A true story. [Vancouver]: Megan Williams, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Inc, ebrary, ed. Towards individualized therapy for multiple myeloma: A guide for choosing treatment that best fits patients. Singapore: World Scientific Publishing Co., 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Carpe diem: Enjoying every day with a terminal illness. Boston: Jones and Bartlett Publishers, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wagner, John R. Thirty and terminal: Cancer survival. Seattle, WA: Infinity Pub., 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Keeping your sense of tumour: My fight against myeloma, pneumonia, septic shock, chest infections, shingles - and an ingrowing toenail!!! Peterborough: Fastprint Publishing, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Brunskill, S. J. An exploration of the factors that constitute quality of life for patients with a diagnosis of multiple myeloma. Oxford: Oxford Brookes University, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Myeloma patients"

1

Badros, Ashraf. "Thalidomide in Patients with Relapsed Multiple Myeloma." In Myeloma Therapy, 205–27. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-564-0_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ailawadhi, Sikander, and Chanan-Khan Asher. "Management of Multiple Myeloma Patients with Renal Dysfunction." In Myeloma Therapy, 499–516. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-564-0_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sara, Bringhen, and Palumbo Antonio. "Therapy for Patients not Eligible for Autologous Transplant." In Myeloma Therapy, 99–112. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-564-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nucci, Marcio, and Elias J. Anaissie. "Multiple Myeloma." In Managing Infections in Patients With Hematological Malignancies, 189–209. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-415-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Miguel, San J. F., and M. V. Mateos. "Bortezomib as Induction Therapy in Patients with Multiple Myeloma." In Myeloma Therapy, 253–63. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-564-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mohty, Mohamad, Florent Malard, and Jean-Luc Harousseau. "Treatment of transplant-eligible patients." In Handbook of Multiple Myeloma, 29–40. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-18218-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Boyle, Eileen M., Charline Legrand, Hélène Demarquette, Stéphanie Guidez, Charles Herbaux, Xavier Leleu, and Thierry Facon. "Treatment of elderly patients with myeloma." In Handbook of Multiple Myeloma, 41–63. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-18218-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Manier, Salomon, Artur Jurczyszyn, and David H. Vesole. "Bridging Chemotherapy: Multiple Myeloma." In The EBMT/EHA CAR-T Cell Handbook, 127–29. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_24.

Full text
Abstract:
AbstractIn the phase 2 KarMMa study, 88% of the patients received bridging therapy with only a 5% response (Munshi et al. 2021). In the CARTITUDE 1 trial, 75% of the patients received bridging therapy, with a reduction in tumour burden observed in 34% of the patients prior to cilta-cel infusion, but no patients achieved a CR or better while on bridging therapy (Madduri et al. 2019). Bridging therapy is recommended for virtually all patients. An exception can be discussed for patients with slowly progressive disease, who may not need to receive bridging therapy after leukapheresis; however, this strategy exposes them to a risk of rapid progression later during the manufacturing period. In the future, with allogeneic CAR-T cells, bridging therapy will likely not be necessary because the time between patient inclusion and CAR-T cell infusion is much reduced.
APA, Harvard, Vancouver, ISO, and other styles
9

Yakoub-Agha, Ibrahim, and Hermann Einsele. "Multiple Myeloma." In The EBMT/EHA CAR-T Cell Handbook, 87–90. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_16.

Full text
Abstract:
AbstractTo date, over 100 clinical trials investigating the use of CAR-T cells in MM have been registered at clinicaltrials.gov. Although several CD19-directed CAR-T cell products have been approved (Ghobadi 2018; Yassine et al. 2020), CD19 surface expression on plasma cells is limited or absent, leading to uncertain efficacy in clinical trials that used anti-CD19 alone in patients with MM (Garfall et al. 2015, 2019). Using superresolution microscopy, CD19 can be detected on a large proportion of myeloma cells, which could explain the successful targeting and lysis of myeloma cells by CD19-detecting CAR-T cells (Nerreter et al. 2019). Of note, some ongoing studies in which CD19 is targeted in combination with other antigens, especially BCMA, are being conducted (Beauvais et al. 2020).
APA, Harvard, Vancouver, ISO, and other styles
10

Yee, Andrew J., and Noopur S. Raje. "Treatment of Patients in First or Second Relapse." In Personalized Therapy for Multiple Myeloma, 77–102. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-61872-2_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Myeloma patients"

1

Gopan, Gayatri, Geetha Narayanan, Sreejith G. Nair, Prakash Purushothaman, Rona Joseph, Rekha A. Nair, and Jagathnath Krishna. "Outcome of Treatment in Elderly Myeloma—A Single-Centre Experience." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735368.

Full text
Abstract:
Abstract Introduction Multiple myeloma (MM) accounts for approximately 1% of all cancers and 10% of all hematologic malignancies. In our institution, we see around 200 patients with myeloma every year. We present our experience with multiple myeloma in the patients aged more than 60 years. Objectives This is a retrospective study of 300 newly diagnosed multiple myeloma patients above 60 years of age treated in the Department of Medical Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, India, during the period between 2014 and 2017. The medical records of the patients were studied and following data were collected: demographic and clinical details, diagnostic and staging workup, primary treatment, response assessment, relapse, and survival. Survival was estimated using the Kaplan–Meier method. Results A total of 300 patients were included in the study. The median age was 66 years with a male-to-female ratio of 1.4:1. The common clinical presentations were backache (134), fatigue (49), lower respiratory infection (20), and paraparesis (14). Monoclonal protein was immunoglobulin (Ig)-G in 199 patients (66.6%), IgA in 52 patients (17.4%), IgM in 2 patients, and IgD in 1 patient. Light-chain disease was seen in 42 patients (14%). One hundred and sixty patients (53.5%) had ISS stage III. Only 285 patients received treatment, of which 203 (67.8%) received bortezomib-based regimen, - bortezomib and dexamethasone (BD; 33.4%); bortezomib, lenalidomide, and dexamethasone (BLD; 19.7%); bortezomib, cyclophosphamide, and dexamethasone (VCD; 8.7%); bortezomib, thalidomide, and dexamethasone (BTD; 2.3%); and bortezomib, melphalan, and prednisolone (3.7%). Nonbortezomib-based regimens used were melphalan and prednisolone (MP) alone or with thalidomide or lenalidomide (15%), lenalidomide and dexamethasone (LD; 10.4%), and thalidomide and dexamethasone (TD; 2%). Response assessment was done as per IMWG guidelines. Fifty-seven (26.3%) patients achieved complete response (CR), 94 (43.3%) achieved very good partial response (VGPR), 19 (8.8%) attained partial response (PR), 15 (5.6%) had stable disease, and 46 (15.4%) developed progressive disease. With bortezomib-based regimens, 119 patients (58.3%) achieved CR/VGPR, and with non-bortezomib based regimens, 42 patients (51.2%) achieved CR/VGPR. One hundred and forty-three patients (47.8%) received maintenance therapy of which 79 received maintenance with bortezomib, 49 with lenalidomide, and 15 with thalidomide. The average duration of maintenance was 24 months. Second-line chemotherapy regimens were used in 37 patients. Agents used were MP, LD, TD, and VCD. With second-line treatment, 15 patients achieved VGPR, 10 patients achieved partial response, and 25 patients developed progressive disease. Third-line chemotherapy regimens were used in 22 patients and the regimens used were pomalidomide and dexamethasone, MP, TD, LD, vincristine, doxorubicin, and dexamethasone and carfilzomib and dexamethasone. At a median follow-up of 34 months, the 2-year overall survival (OS) was 68%. The median progression-free survival was 21 months. The 2-year OS for patients receiving initial bortezomib-based regimen was 67.8% and non-bortezomib based regimen was 68% which was similar. Conclusion In this study, CR/VGPR rates and 2-year OS in patients treated with bortezomib and non-bortezomib based regimens were not statistically significant.
APA, Harvard, Vancouver, ISO, and other styles
2

Papageorgiou, L., P. Vandreden, L. Garderet, I. Elalamy, and G. Gerotziafas. "International Myeloma Working Group (IMWG) score accuracy in multiple myeloma patients: need for action." In 65th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1728212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Corradini, Andrea, Martin Bøgelund Hansen, and Toma Savic. "An Application for Measuring Frailty of Myeloma Cancer Patients." In PETRA '16: 9th ACM International Conference on PErvasive Technologies Related to Assistive Environments. New York, NY, USA: ACM, 2016. http://dx.doi.org/10.1145/2910674.2910695.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Corradini, Andrea, Martin Hansen, and Toma Savic. "Measuring the Frailty Index of Multiple Myeloma Cancer Patients." In 10th EAI International Conference on Pervasive Computing Technologies for Healthcare. ACM, 2016. http://dx.doi.org/10.4108/eai.16-5-2016.2263785.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yousef, Mira, Jenenne Geske, and Birgit Khandalavala. "BMI and Waist Circumference in Patients with Multiple Myeloma." In NAPCRG 50th Annual Meeting — Abstracts of Completed Research 2022. American Academy of Family Physicians, 2023. http://dx.doi.org/10.1370/afm.21.s1.4375.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brignoni, Marisel. "Abstract A43: [Advocate Abstract:] Dot4life multiple myeloma for Caribbean patients." In Abstracts: Tenth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 25-28, 2017; Atlanta, GA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7755.disp17-a43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Solano, M., C. Faure, C. Pain, P. Loriod, AC Maes, P. Marguet, M. Kroemer, et al. "4CPS-378 Oral therapy adherence and satisfaction in patients with multiple myeloma." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.210.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cransac, A., B. Sadon, S. Marty-Quinternet, C. Pernot, D. Caillot, and M. Boulin. "DI-053 Adherence to immunomodulatory drugs in patients with multiple myeloma." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.300.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lanzola, Giordano, Rosangela Boninsegna, Eleonora Losiouk, Elisa Maria Zini, Silvana Quaglini, Virginia Ferretti, and Alessandro Corso. "An mHealth app counseling patients and general practitioners about Multiple Myeloma." In 2017 IEEE 3rd International Forum on Research and Technologies for Society and Industry - Innovation to Shape the Future for Society and Industry (RTSI). IEEE, 2017. http://dx.doi.org/10.1109/rtsi.2017.8065889.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Fernández López, EG, MM Viña Romero, J. Merino Alonso, JA De Leon Gil, I. Gonzalez Perera, and JA Martin Conde. "4CPS-085 Improved access to chemotherapeutic treatment in patients with multiple myeloma." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.186.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Myeloma patients"

1

Conte, Ianina. The role of apixaban, aspirin and enoxaparin as thromboprophylaxis in patients newly diagnosed with multiple myeloma – an open label randomised feasibility study. National Institute for Health Research, July 2021. http://dx.doi.org/10.3310/nihropenres.1115157.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jiang, Zhiping, Ao Zhang, Shuxing Wang, Quanlei Ren, and Yizhu Wang. Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0013.

Full text
Abstract:
Review question / Objective: A meta-analysis was performed to investigate prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia. Condition being studied: Some MDS or AML patients have ASXL1 mutations while others haven’t. Main outcome(s): We used OS as the primary endpoint and AML transformation as the secondary endpoint. OS was defined as either death (failure) or survival at the last follow-up. AML transformation was defined as starting when the patient entered the trial and proceeding to the time of AML diagnosis.Combined HRs and 95% CIs for OS and AML transformation were used to evaluate the prognostic effect of ASXL1 mutations using the generic inverse variance method.
APA, Harvard, Vancouver, ISO, and other styles
3

Kungwankiattichai, Smith, Ben Ponvilawa, Claudie Roy, Pattaraporn Tunsing, Florian Kuchenbauer, and Weerapat Owattanapanich. Maintenance with Hypomethylating Agents after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0078.

Full text
Abstract:
Review question / Objective: P: Patients with AML or MDS after allo-SCT; I: Hypomethylating agents after allo-SCT; C: Observation after allo-SCT; O: Overall survival rates. Condition being studied: Hypomethylating agents (HMAs) seem to have a range of properties favorable to post-allogeneic hematopoietic stem cell transplantation (allo-SCT) maintenance in acute myeloid leukemia (AML) patients. This meta-analysis was performed to review all relevant studies to compare the outcomes of patients undergoing allo-SCT for AML or MDS receiving HMA maintenance therapy with observation only. Information sources: The systematic search of the Embase and MEDLINE databases identified 4,416 articles, from which 512 duplicates were removed. This resulted in 3,904 articles available for title and abstract review. Subsequently, 3,875 articles were excluded as the article type and study design did not fulfill the inclusion criteria, or there was no report on a primary outcome of interest. The remaining 29 articles underwent full-length review and 18 of those were excluded for the aforementioned reasons. Ultimately, the eligibility criteria for our meta-analysis were met by 11 studies: 2 RCTs, 1 prospective cohort study, and 8 retrospective cohort studies.
APA, Harvard, Vancouver, ISO, and other styles
4

Qin, Han, and Ying Chao Yang. Effects of isocitrate dehydrogenase mutations on treatment outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fan, Junjie, Li Gao, Jing Chen, and Shaoyan Hu. Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2020. http://dx.doi.org/10.37766/inplasy2020.9.0019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Myeloma patients' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography